Emphysema is not a specific stage of COPD. It is one of the conditions that falls under the COPD umbrella, alongside chronic bronchitis and small airway disease. You can have emphysema at any stage of COPD, from mild to very severe, and the amount of emphysema you have doesn’t always match up neatly with your COPD stage number. The two are measured differently, which is why this question is so common and so confusing.
How Emphysema Fits Inside COPD
COPD is a broad diagnosis that covers several types of lung damage sharing one thing in common: airflow that’s permanently restricted. Emphysema is one specific type of damage within that diagnosis. It involves the permanent destruction of the tiny air sacs (alveoli) deep in the lungs. As those sacs break down, they merge into larger, less efficient spaces. That means less surface area for oxygen to cross into your bloodstream and less elastic recoil to push air back out when you exhale.
Some people with COPD have mostly emphysema. Others have mostly chronic bronchitis, which involves inflamed, mucus-producing airways. Many have a mix of both. When emphysema is the dominant pattern, the disease tends to come with more severe airflow limitation and can progress faster. A study in the American Journal of Respiratory and Critical Care Medicine found that people whose lung function declined most rapidly (losing around 63 mL of air capacity per year, compared to an average of 32 mL per year) had significantly more emphysema visible on CT scans.
How COPD Stages Are Actually Determined
COPD stages are based on a breathing test called spirometry, not on how much emphysema is present. During this test, you blow into a device as hard and fast as you can. Two numbers matter most: how much air you can force out in one second, and the total amount you can exhale. If the ratio between those two falls below 0.70, you meet the threshold for a COPD diagnosis.
Once COPD is confirmed, severity is graded by how much of your expected lung capacity remains. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) system uses four grades:
- GOLD 1 (Mild): 80% or more of predicted capacity remains
- GOLD 2 (Moderate): 50% to 79% of predicted capacity
- GOLD 3 (Severe): 30% to 49% of predicted capacity
- GOLD 4 (Very Severe): less than 30% of predicted capacity
Notice that none of these grades mention emphysema. A person with extensive emphysema on a CT scan could still be GOLD 1 if their spirometry numbers haven’t dropped much yet. Conversely, someone with relatively little visible emphysema could be GOLD 3 because their small airways are severely narrowed. The stage reflects how well air moves through your lungs overall, not what’s causing the obstruction.
Why Emphysema Can Be Present Before Staging Begins
One of the trickiest things about emphysema is that it can show up on imaging before spirometry catches it. CT scans can reveal destroyed air sacs while your breathing test still looks relatively normal. This happens because the lungs have a large reserve capacity. You can lose a meaningful amount of tissue before the loss translates into measurable airflow obstruction.
Research comparing CT findings across groups (never-smokers, at-risk smokers, and confirmed COPD patients) shows that emphysema scores get progressively worse as COPD severity increases. But the relationship isn’t perfectly linear. Some at-risk smokers already show emphysema on imaging even though they don’t yet meet the spirometry threshold for a COPD diagnosis. This is why doctors sometimes describe emphysema as existing on a continuum, with structural damage building quietly before it crosses the clinical line into a formal COPD stage.
What Emphysema Does to Oxygen Exchange
Beyond spirometry, doctors sometimes measure how efficiently your lungs transfer oxygen into your blood. This gas transfer test captures something that spirometry alone misses: the destruction of the capillary-rich walls where oxygen exchange actually happens. Emphysema specifically targets those walls, thinning and simplifying them until there’s far less surface area available for gas exchange.
Results from this test are reported as a percentage of the expected value for someone your age and size. A result between 61% and 75% of predicted is considered mild impairment. Below 40% is severe. Because emphysema directly destroys the tissue responsible for gas exchange, people with emphysema-dominant COPD often score lower on this test than people whose COPD is driven more by airway inflammation. It’s one of the tools that helps doctors understand not just your COPD stage, but the type of damage driving it.
How Symptoms and Treatment Shift With Severity
The GOLD system doesn’t stop at those four airflow grades. Current guidelines also sort patients by their symptoms and how often they experience flare-ups (exacerbations). Under the latest framework, patients fall into groups: Group A (few symptoms, few flare-ups), Group B (more symptoms, few flare-ups), or Group E (frequent or severe flare-ups). This second layer of classification directly shapes treatment decisions.
For someone with emphysema-dominant COPD in the earlier, less symptomatic categories, treatment typically starts with a single long-acting inhaler that helps keep airways open. People in Group E, who are dealing with frequent exacerbations, are generally started on two types of inhaled bronchodilators together. If blood tests show elevated levels of certain white blood cells (eosinophils above 300 cells per microliter), a third inhaled medication, a corticosteroid, may be added.
The practical experience changes as emphysema progresses. Early on, breathlessness might only show up during vigorous activity. Over time, even routine tasks like climbing a short flight of stairs or carrying groceries can leave you winded. In advanced stages, supplemental oxygen may become part of daily life. The rate at which this progresses varies widely. Some people lose lung function slowly over decades, while rapid decliners can lose twice the average amount each year.
When Emphysema Appears Unusually Early
Most emphysema develops after years of smoking, typically becoming noticeable in the 50s or 60s. But if emphysema is diagnosed between ages 40 and 50, or if there’s a family history of early lung disease, a genetic condition called alpha-1 antitrypsin deficiency may be involved. This inherited condition leaves the lungs without enough of a protective protein, making the air sacs vulnerable to damage even without heavy smoking exposure.
The National Heart, Lung, and Blood Institute recommends that anyone with a family member who has this deficiency, or who develops COPD unusually early, get tested. A blood test can screen for it, and a genetic test confirms the specific mutation. Identifying this cause matters because it opens up a specific treatment (protein replacement therapy) that isn’t part of standard COPD management, and it carries implications for siblings and children who may also carry the gene.